Adjuvant immunotherapy after melanoma surgery reduces risk of cancer recurrence


In melanoma patients who are also treated with the immune therapy pembrolizumab after surgery, the risk of recurrence of the disease is almost twice as small as in patients who receive a placebo. This was shown by a randomized study in 23 countries, of more than 1000 melanoma patients, of whom 50 were from the Netherlands Cancer Institute.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.